Dermatology News: Who’s at risk for depression on isotretinoin?: https://bit.ly/32AioXp Topical tapinarof effective in pivotal psoriasis trials: https://bit.ly/3pma0o0 Methotrexate users need tuberculosis tests in high-TB areas: https://bit.ly/3f0DcMV *  *  * Keeping up with the literature on atopic dermatitis (AD) is a challenge, with eight new articles posted on PubMed a day in 2020. Vincent A. DeLeo, MD, talks to Lawrence F. Eichenfield, MD, about quality of life in pediatric AD patients and how the condition affects parents/guardians, particularly in the form of sleep disturbances. Dr. Eichenfield also discusses studies that explore the impact of bathing frequency on the severity of AD as well as notable treatment advances in topical and systemic therapies in recent years. Reflecting on future research, Dr. Eichenfield posited if “recognizing significant disease early and instituting our more aggressive therapies early, will that change the development of comorbidities and will that burn out the disease more quickly or get sustained remission or cure as compared to just waiting?” Article: https://bit.ly/3f0DrHP Downloadable PDF: https://bit.ly/3lzuUy1 *  *  * Hosts: Nick Andrews, Vincent A. DeLeo, MD (University of Southern California, Los Angeles) Guest: Lawrence F. Eichenfield, MD (division of pediatric dermatology, departments of dermatology and pediatrics, University of California, San Diego, and Rady Children’s Hospital, San Diego) Disclosures: Dr. DeLeo is a consultant for Estée Lauder. Dr. Eichenfield is an investigator for AbbVie, LEO Pharma, Pfizer, Regeneron, and Sanofi Genzyme. He also is a consultant for Almirall, Dermavant Sciences, Dermira, DS Biopharma, Eli Lilly, Forte Biopharma; Galderma Laboratories, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Otsuka Pharmaceutical, Pfizer, Regeneron Pharmaceuticals, and Sanofi Genzyme. Show notes by: Allegra Sparta, Melissa Sears *  *  * You can find more of our podcasts at http://www.mdedge.com/podcasts Email the show: podcasts@mdedge.com